Illumina launches next generation of TruSight Oncology 500

Illumina (ILMN) announced the launch of the next generation of TruSight Oncology 500, its flagship cancer research assay that enables comprehensive genomic profiling. Comprehensive genomic profiling, or CGP, is a critical tool to accelerate access to precision medicine by providing a molecular tumor profile to labs advancing research in therapy selection and clinical trial eligibility. TruSight Oncology 500 version 2 offers a streamlined sample-to-analysis workflow and reflects Illumina’s commitment to serving customers with the highest quality and most rigorously tested solutions. From a small tissue sample, TSO 500 v2 assesses hundreds of genes across all variant classes and immuno-oncology biomarkers to facilitate therapy selection research. Research shows that when CGP is performed early in a cancer patient’s diagnosis, it leads to better personalized treatment and outcomes. For the first time, homologous recombination deficiency, or HRD, status will be included for all samples analyzed, at no additional cost. HRD analysis is powered by a gold-standard Genomic Instability Scoring (GIS) algorithm licensed from Myriad Genetics. This will expand research into the value of the HRD biomarker in more cancer types.